Current Edition


Gilead’s Kite flies higher as Yescarta leads CAR-T therapy class to earlier lymphoma treatment

Existing CAR-T therapies have been saved for blood cancer patients who’ve tried multiple treatments—until now. With a first-in-class nod, the FDA has cleared Yescarta, a …

Continue Reading →

Roche’s Polivy to hit $2.4B as doctors expect ‘significant switching’ in newly diagnosed lymphoma: analyst

Roche Pharmaceuticals CEO Bill Anderson recently pegged lymphoma drug Polivy’s potential expansion into newly diagnosed patients as a multibillion-dollar opportunity. Now, at least one analyst …

Continue Reading →
Bristol Myers

Novartis’ Kymriah flops in earlier lymphoma use, where Gilead, Bristol Myers CAR-T rivals succeeded

Novartis’ Kymriah is losing its shot at a key market expansion opportunity in second-line lymphoma, where CAR-T rivals from Gilead Sciences and Bristol Myers Squibb …

Continue Reading →

Roche snags coveted Polivy win in newly diagnosed lymphoma. But is it enough to change 2 decades of established treatment practices?

After two years of meager sales for Polivy, Roche is trumpeting a much-coveted clinical win that could open up a blockbuster market for the drug. …

Continue Reading →

Xynomic Pharma Plans 4 Clinical Trials of Abexinostat for Lymphoma

 Xynomic Pharma announced it has completed a new Series B financing round and now will initiate eight clinical trials, four of which are for different types of …

Continue Reading →

Viracta Initiates Treatment of First Patient in EBV+ Lymphoma Clinical Trial with Tractinostat

Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, has initiated treatment of the first patient …

Continue Reading →